Chris Pasquale
Stock Analyst at Guggenheim
(n/a)
# 4,371
Out of 4,791 analysts
6
Total ratings
n/a
Success rate
-28.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Pasquale
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZIMV ZimVie | Initiates: Neutral | n/a | $10.56 | - | 1 | Mar 18, 2022 | |
| ICAD iCAD, Inc. | Downgrades: Neutral | n/a | $1.95 | - | 2 | Jan 18, 2022 | |
| DXCM DexCom | Upgrades: Buy | $145 | $68.14 | +112.80% | 1 | Jan 7, 2022 | |
| COO The Cooper Companies | Upgrades: Buy | $124 | $81.23 | +52.35% | 1 | Jan 3, 2022 | |
| PRCT PROCEPT BioRobotics | Initiates: Buy | $45 | $57.74 | -22.06% | 1 | Oct 11, 2021 |
ZimVie
Mar 18, 2022
Initiates: Neutral
Price Target: n/a
Current: $10.56
Upside: -
iCAD, Inc.
Jan 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.95
Upside: -
DexCom
Jan 7, 2022
Upgrades: Buy
Price Target: $145
Current: $68.14
Upside: +112.80%
The Cooper Companies
Jan 3, 2022
Upgrades: Buy
Price Target: $124
Current: $81.23
Upside: +52.35%
PROCEPT BioRobotics
Oct 11, 2021
Initiates: Buy
Price Target: $45
Current: $57.74
Upside: -22.06%